Acceleron Pharma

Acceleron Pharma was a Cambridge, Massachusetts-based biopharmaceutical company focused on the discovery and development of transformative therapies that regulate the TGF-β superfamily of proteins. Its lead asset, sotatercept, was a first-in-class activin receptor fusion protein for pulmonary arterial hypertension. Founded in 2003, the company went public in September 2013 on NASDAQ (XLRN) and had approximately 312 employees at the time of its acquisition. Merck acquired Acceleron in November 2021 for $11.5 billion.